Buprenorphine has been widely used for post-operative analgesia in laborat ory animals. Clinical ef®cacy has been dem onstrated in both subjective and objective pain assessment schemes, however doubts have been expressed as to its value as an analgesic. Initial dosage recommendations were based on analgesiometric studies. It is unlikely, however, that the pain elicited in analgesiometric tests is comparable to post-operative pain. T his has resulted in recommendations of excessive dose rat es and inappropriate clinical indications. Studies involving tests of the ef®cacy of buprenorphine for alleviating behavioural or other signs of tonic (post-surgic al ) pain provide a more appropriat e estim at ion of the analgesic capabi lities of the drug. However, buprenorphine also has major effects upon the behaviour of normal (unoperated) animals, and this makes assessments of ef®cacy dif® cult with some of the systems used for scoring clinical pain. Nevertheless, our most recent studies of the effects of buprenorphine upon pain-related behaviours in rats support the view that it is an effective post-operative analgesic. T his short review critically reappraises the role of buprenorphine in this capacity and discusses a rational approach to the relief of pain in laboratory animals. We conclude that buprenorphine remains a valuable agent for pain relief in a wide range of animal species when used in an appropriate manner. (2002) 36, 322-343 C o rre spond e nc e to : J. V. Ro ugh a n E-m a il: J.V.Ro ugh a n@ncl.a c .uk
The analgesic effects of buprenorphine
Buprenorphine has been extensively used as an analgesic both in laboratory and companion animals for almost two decades. It has recently been licensed for use in dogs and cats in the UK (`Vetergesic', Alstoe Veterinary, York, UK). T he potent analgesic effects of buprenorphine have been described in anim als presumed to be experiencing severe pain (Leese e t a l. 1988 ), and also varying degrees of post-surgical pain in clinical studies with rats, cats, dogs, pigs, sheep and also in man (Tabl e 1). T he antinociceptive properties of buprenorphine have also been determ ined, using numerous analgesiometric tests in a range of different species (see Table 2 ). An expanded account of availabl e data and more general conclusions concerning the ef®cacy of buprenorphine in some of these tests can be found in Table 3 . Collectively, the results of the clinical and laboratory studies that have been undertaken provide compelling evidence that buprenorphine is not only a potent analgesic, but also that its durat ion of acti on is considerably longer than either morphine or pethidine (from between 6 and 12 h) although this Table 1 Summary Flecknell et al. 1999 Rat=Wistar 4 cm midline LAP, 2 min visceral manipulation 0.05; s.c. Pre-and post-op BUP treated groups showed improved general mobility relative to saline controls. Pre-op BUP showed less reduction in food intake than controls. Conclusion: Surgery causes paininconclusive whether pre-op BUP is a more effective pain alleviation strategy.
Hayes & Flecknell 1999
Rat=SD & DA 6 cm LAP; 5 min visceral manipulation 0.01 or 0.05; s.c. No analgesia groups lost weight and had reduced food and water consumption. All BUP treated rats lost less weight than controls at 1 d. In SD rats, low dose BUP, immediately or 9 h post-op attenuated weight loss.
Higher dose, no additional bene t or detrimental.
DA rats required 26high dose for similar bene t; may need higher dose. 
Tabuchi & Takahashi 2000
Route of administration is given by: subcutaneous (s.c.); intraperitoneal (i.p.); intravenous (i.v.); intramuscular (i.m.) and oral (p.o.). LAPˆlaparotomy depends on the species and method of assessment (Hal l & Clarke 1991 ) . Despite this, there have recently been reports claiming that buprenorphine is an ineffective analgesic for severe pain in rat s and mice (Gades e t a l. 2000, Gillingham e t a l. 2001, Marti n e t a l. 2001 ). Added to this, claims that buprenorphine induces the undesirable side effect of pica behaviour (Clark e t a l. 1997, Bender 1998 , Jacobson 2000 , have raised further concerns regarding its suitability for use as a post-operative analgesic in rat s. Buprenorphine is one of the most widely-used opioid analgesics in laboratory and companion animals, as shown by the various surveys of its use in veterinary clinical practice (Dohoo & Dohoo 1996 , Watson e t a l. 1996, Capner e t a l. 1999, Lascelles e t a l. 1999, Joubert 2001 ) and is the drug of choice at most UK research the period over which this sig. diff. was maintained.
The highest doses of nalbuphine and butorphanol showed reduced analgesic activity, whereas increasing the buprenorphine dose progressively increased the duration of analgesia obtained: from 150-780 min.
Flecknell &
Liles 1990
Cat Skin twitch: cutaneous thermal stimulation (0-70 C) 0.01; i.m. The thermal threshold in saline group was increased at 2 and 6 h following BUP administration by 5.6 and 5.8%, respectively. At 4 h after i.m. morphine (0.2 mg=kg ¡1 ) the threshold was increased by 11.4%. Conclusion: Increase in thermal threshold slow to develop with either i.m. BUP or morphine and occurs when plasma levels are low.
Robertson et al. 2000
Route of administration is given by: subcutaneous (s.c.); intraperitoneal (i.p.); intravenous (i.v.); intramuscular (i.m.) and oral (p.o.). LAPˆlaparotomy establ ishments for alleviat ing post-operati ve pain (Hawkins 2002 ) . T his critical review aim s to clarify the situation concerning the antinociceptive effects of buprenorphine and its value as a post-operative analgesic.
Background and basic pharmacology
Buprenorphine is a semi-synthetic, highly lipophilic derivative of oripavine and a partial mu opioid agonist. Buprenorphine is most frequently classed as a mu receptor agonist with antagonist effects at kappa opioid receptors (Leander 1988, see Cowan 1995 for review). However, since it has been shown that buprenorphine can antagonize the antinociceptive effects of morphine in rat s and mice, it has also been classed as a mu receptor antagonist and kappa receptor agonist; the latter also being considered a site of some of the drug's antinociceptive actions (Pick e t a l. 1997 ). T his diversity of views mirrors the complexity of interactions that have been demonstrated between buprenorphine and opioid receptors. Because of its ability to antagonize the effects of full mu agonists such as morphine, pethidine and fentanyl, buprenorphine has also been studied for its potential in treati ng opioid dependency (Jasin ski e t a l. 1978 ). For the most part, however, research into the effects of buprenorphine has focussed on the antinociceptive (analgesic ) properties of the drug. Most studies of the ef®cacy of buprenorphine have used analgesiometric tests, and these indicate that at equi-analgesic dosages (the dosage required to obtain a given analgesic effect), buprenorphine is between 25±50 times more potent than morphine in humans (for exam ple, Jasinski e t a l. 1978). In rats and mice it is 25±40 times more potent than morphine when administered parenterally (Cowan 1995 ) and 6±10 tim es more potent when given orally (Cowan e t a l. 1977a). It reaches its maxim um antinociceptive effect at approxim at ely one hour following subcutaneous adm inistration in rats (Dum & Herz 1981) .
In common with the mixed agonist± antagonist analgesics such as pentazocine, nalbuphine and butorphanol, buprenorphine exhibits a plateau in analgesic effect during analgesiometric assays. Having reached its maximal effect, which is normally less than that of a pure mu agonist, adm inistration of additional drug produces either detrim ental effects (Jablonski e t a l. 2001) or no additional analgesia, although the durat ion of analgesic effect may be prolonged (Flecknell & Liles 1990 ) . T his`ceiling effect' has been dem onstrated in several species, including rats (Kareti e t a l. 1980, Dum & Herz 1981, Jablonsk i e t a l. 2001 ), mice (Swedberg 1994 ) and rabbit s (Flecknell & Liles 1990 ) . Analgesiometric studies have also shown that at doses in excess of 1 mg=kg ¡1 in rats, the antagon istic effects of buprenorphine predominate and the analgesic effects decline (Dum & Herz 1981 , Lizasaoin e t a l. 1991 ). T his gives rise to a`bell-shaped' doseresponse curve for buprenorphine. As discussed later, this is unlikely to have any signi®cant clinical relevance.
T he pharm acological pro®le of buprenorphine is complex, and this underlies some remaining uncertaint ies as to the exact mechanism by which its actions are exerted. As a result of this, buprenorphine has been described as`unique' (Jasin ski e t a l. 1978 ), since differential (agoni st or antagonist) effects occur at mu and kappa receptors depending on the dosage that is administered (Pick e t a l. 1997 ).
Analgesiometric testing
Analgesiometric studies have been used to estimate initial dosages of buprenorphine for clinical use in anim als (Flecknell 1984 ) , since no controlled clinical trials had been undertaken at that time. T hese initial dose rates were subsequently revised, as new data based on assessments of clinical signs of pain became available. However, reliance is still placed on analgesiom etric dat a as a means of assessing the likely duration and ef®cacy of buprenorphine and other analgesics.
Analgesiometric tests are used to determine analgesic potency by measuring antinociceptive effects. and Le Bars e t a l. 2001). In all of these tests, analgesic potency is presumed to be measured by determining drug-in duced changes in the tim e required for the anim al to react when the stimulus is applied. Analgesiometric tests provide a convenient means of measuring the antinociceptive effects of drugs, but the neurological mechanisms involved may not be equivalent to those responsible for clinical pain. It is therefore not appropriate to make analgesic dosage recommendations based solely on the results of these types of test.
T he situation is further complicated by the differi ng results from different types of analgesiometric test. A summary of available data concerning estimates of the ef®cacy (ED 50 values) of buprenorphine is given in Table 2 . An explanat ion for this wide variation in results shown in the table may be provided by examining the different tests used.
Phasic and tonic nociception
Depending upon the stimulus type, the various analgesiometric testing techniques can be sub-divided into two classes. Brief nociceptive effects, such as occur in the tail-¯ick or hot-plate tests are termed phasic, whereas nociceptive inputs that produce more prolonged effects are known as tonic. T he morphological differences between phasic and tonic pain responses have led some authors to propose that they have distinct neuropharmacological and neurophysiological bases (Cowan 1995 ) . Based on evidence from brain lesioning studies, that showed differential actions of morphine in phasic and tonic nociceptive assays, Abbot t e t a l. (1982 ) argued strongly that there were fundamental differences between the effects of phasic and tonic nociceptive stim uli. Apart from the obvious differences in terms of durati on, these authors proposed that the tail-¯ick assay and other thermal-based techniques may primarily involve only a spinally-mediated re¯ex following nociceptive stimulation. In these circumstances withdrawal occurs in response to a rapidly rising nociceptive input, but at the lowest possible threshold. In contrast, tonic nociception involves more complex central nervous system (CNS) mechanisms and structures.
T here are also differences in the peripheral transduction mechanisms involved in tonic and phasic nociception. Phasic analgesiometric tests primarily involve A-delta mechanothermal receptors that are act ivated by high intensity stim ulation and relay inform at ion to the dorsal horn nuclei of the spinal cord. By contrast, tonic nociceptive stimuli are carried by C-polymodal ®bres that are activat ed by stimuli of low or intermediate frequency (Yeom ans & Proud®t 1994 , 1996 .
T here is strong evidence that phasic and tonic nociceptive systems are distinct not only in morphology, but also in term s of their neurophysiological and neurochemical transduction mechanisms. T his has been noted by Welsh and Nolan (1995), who concluded that differences occur in the central processing of noxious inform ati on elicited by mechanical or thermal stimuli. Such differences probably underlie the ®ndings of Hayes e t a l. (1987) that the abdom inal constriction test, and the paw and tail pressure tests are more effective than tests that employ heat for determ ining the relati ve analgesiometric potencies of opioid drugs in mice, rats and guineapigs. Schmauss and Yaksh (1984 ) studied the effects of various intrathecallyadministered opioids on the responses of rats in the hot-plate, tail-¯ick and writhing tests. It was found that all the partial agonists studied (pentazocine, buprenorphine and nalorphine) readily blocked visceral chemical nociceptive effects but were considerably less act ive in cutaneous thermal tests. T he authors reached the same conclusion as Yaksh and Rudy (1977 ) and Russell and Yaksh (1981) that selective differences in responses were due, depending on the stimulus type, to the differential coding of spinal afferents, and speci®cally, to the strong af®nity of these substances for kappa rather than mu receptors at the level of the spinal cord. T he results of these studies provide strong support for the classi®cat ion of mechanical and chemical tests (tail pressure and writhing=formalin tests) as more appropriate models of tonic, rather than phasic nociception. Since post-surgical pain involves activation of c-polym odal nociceptors, it is more likely that ef®cacy in tonic analgesiometric tests would better equate with ef®cacy in clinical pain relief (Abbott e t a l. 1982).
T he formalin test (Dubuisson & Dennis 1977, Wheeler-Aceto & Cowan 1991a), unlike thermal or other phasic assays, elicits a two-stage response. T he biphasic nature of this test has provided a model to study components of both phasic and tonic nociception. An acute nociceptive stage (phasic component) that lasts only brie¯y is superimposed on a more continuous bac kground of tonic nociception that may last up to 70 min. T his latter component involves complex postural movements such as bit ing, licking or shaking of the forepaws or the head and neck in response to a more persistent, unavoidable nociceptive input that is based upon actual damage to subcutaneous tissues.
Wheeler-Aceto and Cowan (1991b) examined the possibility that discrepancies in the antinociceptive effects of buprenorphine, compared to consistent effects of morphine, might be due to differential mechanisms of central processing of noxious information. Uniquely, morphine and buprenorphine were compared for antinociceptive ef®cacy in individual rat s exposed to b o th the tail-¯ick test, and subsequently, the form alin test. T his study design differed from most attem pts to compare the potencies of morphine and buprenorphine in that the anim als acted as their own controls. Buprenorphine had full ef®cacy in the formalin test but a signi®cant lack of ef®cacy in the tail-¯ick test. By contrast, morphine was effective across both types of test and also both phases of the form alin test. Furthermore, although the ef®cacy of buprenorphine decreased in doses in excess of 1 mg=kg ¡1 in the phasic stage of the formalin test, this did not occur in the tonic stage of the test. T his dose rate (1 mg=kg ¡1 ) is the traditional ly accepted`cut-off' dosage, above which, when responses are measured using standard analgesiometric techniques, buprenorphine has been found to decline in potency. T his implies that thè bell-shaped' dose-response curve or ceilingeffect may not apply when tonic pain is elicited.
Pharmacological studies have provided further justi®cati on for distinguishing between nociception elicited by phasic and tonic stim uli. Pick e t a l. (1997 ) demonstrated that buprenorphine elicits its analgesic effects primarily at subtype 3 kappa receptors and that this may distinguish its effects from other agents with mu agonist activity. Similar differenti al effects of other kappa agonists in phasic and tonic tests have been reported (Millan & Colpaert 1991, McLaughl in e t a l. 1995, McCormack e t a l. 1998 ). T he data discussed above suggest that high intensity phasic analgesiometric tests are of limited relevance to clinical pain (e.g. Shaw e t a l. 1988 ), consequently, the validity of recommendations concerning clinical ef®cacy, based solely upon the results of such testing is doubt ful (Flecknell 1984, Cooper e t a l. 1997 ).
T his view is supported by a comparison between the dose rates of buprenorphine that are apparently effective in tonic analgesiometric tests, and those that have been proven to be effective in controlled clinical trials. Buprenorphine administered in the range 0.02±0.05 mg=kg ¡1 is effective in att enuating the¯inching response in the lat e phase of the formalin test in rats (Wheeler-Aceto & Cowan 1991b) and buprenorphine administered subcutaneously at 0.06 mg=kg ¡1 is an effective dosage in the mouse writhing test (Huang e t a l. 2001 ). T hese rates compare favourably with the commonly recommended subcutaneous dosage for pain following a standardized laparotom y model in rats of 0.05 mg=kg ¡1 (Flecknell & Waterman-Pearson 2000 ) . In contrast, the results of phasic tests indicate dose rates from 10±20 tim es higher. As mentioned earlier, this difference is of considerable clinical sig-ni®cance, since the results of phasic analgesiometric tests (hot-plate and tail-¯ick) have led to the recommendation that buprenorphine should not be used to control severe pain in rats and mice (Gades e t a l. 2000 ). We would suggest that results of phasic tests are not appropriate for formulati ng guidelines for clinically effective dose rates.
Recommendati ons concerning the therapeutic use of a particular analgesic should be based directly on evidence of clinical ef®cacy. When such data are not available, the results of tonic nociceptive tests (e.g. form alin test ) may provide useful information for predicting clinically effective dose rates.
Variation in antinociceptive ef cacy of buprenorphine
In people it has been demonstrated that considerable variat ion occurs between each individual's perception of pain, whether this is measured by analogue pain scoring (Lat asch e t a l. 1984 ) or by measurement of the patients' rat e of self-adm inistration of analgesics (Chapm an e t a l. 1997 ). Data on opioid self administration in rat s show similar variation (Colpaert e t a l. 1980 ), hence it is likely that different animals' requirements for analgesics following apparently identical stimulation also vary considerably. T his is most clearly demonstrated in studies that report dat a on individual animals. Using Kaplan±Meier curves (probabilit y of antinociceptive effect vs time), Gades e t a l. (2000 ) report that in a hot-plate test, 25% of rats receiving buprenorphine showed baseline response latencies after only 90 min. Inspection of their data shows similar effects with morphine and butorphanol. In mice subjected to the tai l-¯ick test, their data indicate that 15±20% of the anim als given morphine also showed baseline responses as early as 40 min following drug administrat ion.
As shown in Tabl e 2, in addition to individual variation, the in¯uence of species and strain variation can greatly increase ef®cacy estimates, and these factors must be considered prior to adopting any estimates of drug ef®cacy in a clinical setting. T his wide variation in the ED 50 values obtained in analgesiometric testing reported for buprenorphine also occurs with other opioids. T he dose rates indicated are unlikely to represent the absolute values for clinical use, and it is very likely that the variation in dose rates in analgesiometric testing will be paralleled by similarly large variation in clinical dose rates.
A number of studies have reported major variations between different strains of rodents (Pick e t a l. 1991, Semenova e t a l. 1995, Cook e t a l. 2000 ). T his variation may also depend upon the type of analgesiometric test being used (Semenova e t a l. 1995), the intensity of the stim ulus used (for exam ple, water temperature in the tail-¯ick test) and the tim ing of trials following drug treatm ent. T here are also major differences between sexes, including reports of morphine being up to 9 tim es more potent in male rats than in fem ale rats (Cook e t a l. 2000 ), or between 3.9 and 6.9 times great er in male than in female mice (Kest e t a l. 1999 ). T he degree of variation between strains may also vary depending on the particular analgesic agent used. In a tail-¯ick test, buprenorphine had equivalent ef®cacy in Sprague±Dawley (SD ), Long Evans (LE), Lewis and Fisher344 rats (Morgan e t a l. 1999 ) but there were profound between-strain differences in the ef®cacy of butorphanol, nalbuphine, morphine and levorphanol. In one of only a few studies to exam ine such differences in potency by clinical, rather than analgesiometric means, Jablonsk i e t a l. (2001 ) demonstrated clear differences in the effects of laparotom y in SD and Dark Agouti (DA) rat s given buprenorphine, with SD rat s showing greater sensitivity to the debilitative effects of surgery than DA rat s.
It would seem then, that with all analgesics, potency and duration of action may vary between individuals, and between strains, and the results of different analgesiometric tests also vary. Given the dif®culties of relating analgesiometric data to clinical ef®cacy, it seems the only reliable means of determining appropriate dose rat es for analgesic drugs is by clinical trials, using validated pain scoring systems. T his would enable assessment of an individual animal to con®rm that an appropriate and effective dose of analgesic had been administered following a given surgical procedure.
Assessing the clinical ef cacy of buprenorphine
T here are numerous examples of assessments of the clinical ef®cacy of buprenorphine in different species following a range of surgical procedures (Table 1 ). Although it was not possible to measure pain directly in such studies, the methods of pain assessment used rely upon recognition of the effects of surgery and measuring any changes to these following drug treatm ent. Depending upon the variables measured, these methods of pain assessment can, broadly speaking, be divided into subjective and objective scoring techniques. In both types of scoring system, the rati onale is that if a measurable effect of surgery has been lessened by treatm ent with an analgesic, provided the effects observed are not due to drug treatm ent pe r se (as assessed when the drug is given to normal anim als), it is assumed that an analgesic effect has been detected.
In a subjective clinical assessment, Stanway e t a l. (1996, 2001 ) compared pre-operatively administered morphine and buprenorphine and observed signi®cantly lower pain scores in cats that received buprenorphine (0.01 mg=kg ¡1 ) for 3 h following a range of major and more minor surgical procedures. Despite such positive results, assessments of this type are prone to large variability between assessors and may produce inconsistent data in respect of the analgesic potency and duration of effect of buprenorphine. It is widely accepted that behavioural changes accompany pain (Morton & Grif®ths 1985 ) and this assumption has been incorporated into a de®nition of anim al pain (Zimmerman 1986 ). It has been proposed that these changes can be used to develop objective pain assessment techniques (Kent e t a l. 2000 , Roughan & Flecknell 2001 .
It has been shown in rats that post-operative reductions in food and water consumption, body weight and generalized locomotor activity (Fleck nell & Liles 1991 , Liles & Flecknell 1992 , 1993a ,b, 1994 , Liles e t a l. 1998, Flecknell e t a l. 1999 ) may be used to assess pain, and that the extent to which changes in these parameters occur re¯ects the severity of the surgical procedure (Liles & Flecknell 1993a,b) . T hese effects were att enuated when buprenorphine was administered either subcutaneously (Lil es & Flecknell 1993a ,b, 1994 or orally (Liles e t a l. 1998 , Flecknell e t a l. 1999 , Hayes & Flecknell 1999 , indicat ing that the changes were due to post-surgical pain. As mentioned earlier, this assumption is valid providing that similar changes do not occur when the analgesic treatm ent is administered to normal (unoperated) animals. However, one consistent ®nding in all of these studies is that buprenorphine has a strong in¯uence upon normal behaviour. Most often, buprenorphine has been shown to cause an increase in general levels of activity in both normal (pain-free ) rats (Cowan e t a l. 1977b , Flecknell & Liles 1992 , Liles & Flecknell 1992 , Roughan & Flecknell 2000 and mice (Cowan e t a l. 1977b, Kuribara & Uchihashi 1994, Hayes e t a l. 2000). It also causes reduced food intake, but has relatively litt le effect upon water intake (Lil es & Flecknell 1992 ) . Since the improvements in food intake following buprenorphine treatm ent and surgery were greater than occurred post-operatively in anim als given only saline, or when buprenorphine was given to controls, this param eter was proposed and has been used as a measure of pain. T he effects of buprenorphine in increasing locomotor act ivity are more frustratingly complex. Following surgery, rats often show decreased mobility. When activit y is increased, by some non-speci®c actions of an analgesic, an arti -®cial im pression of improved mobility may be obtained for anim als that are in fact still experiencing pain (Roughan & Flecknell 2000 ) .
From a practical perspective, the limiting factor in pain scoring in rats using measures such as food and water consumption and body weight changes is that the assessments only give a retrospective estimation of the effects of surgery and analgesic treatm ent. What is required is a system of recognizing behavioural signs of pain that would allow determ ination of analgesic requirements, and subsequently, to permit modi®cati on to the analgesic strat egy used, as and when this is required by the individual animal.
Recognizing this, and the need to ®nd painrelated behaviours that are not susceptible to non-speci®c drug in¯uences, recent objective clinical studies have progressively increased the number of behavioural criteria examined as potential indices of pain (Liles e t a l. 1998 , Roughan & Flecknell 2000 , 2001 .
One such study has reported that buprenorphine is less effective than oxymorphone in alleviati ng the symptoms of pain following intestinal resection in rats (Gillingham e t a l. 2001). In this study, buprenorphine was given at the excessively high dosage of 0.5 mg=kg ¡1 s.c. every 6 h, and the authors reported behaviour consistent with pain for up to 32 h post-operatively. Unfortunately this study did not include a parallel control investigation to determine whether the behavioural effects observed following buprenorphine administrat ion were in fact pain related. T he authors do, however, state that similar effects had been observed during development of the model, in that rats given buprenorphine without surgery developed behavioural changes which were subsequently interpreted as pain-related behaviour.
A similar description of the effects of high doses of buprenorphine in rats is provided by Cowan e t a l. (1977b) in which subcutaneous administrat ion at a dose rate of 0.1±0.3 mg=kg ¡1 in normal rats elicited a characteristic hunched or`hedgehog' posture with repetitive licking and biting of the limbs and cage. A recent study by Roughan and Flecknell (2000 ) at tem pted to develop a behaviourbased technique for assessing pain severity in rats given buprenorphine either alone, or prior to laparotom y. In an attem pt to overcome some of the problems related with buprenorphine and its effects on behaviour, the authors used a great er number of individual behaviours than in any previous attem pts at pain scoring. Very large-scale behaviour changes occurred throughout a 24 h period following buprenorphine administrati on, irrespective of whether anim als underwent surgery or were unoperated controls.
One notabl e ®nding was that in addition to the well-documented increases in locomotor activity that may frustrate accurate pain scoring, control rats given 0.05 mg=kg ¡1 buprenorphine also showed a signi®cant reduction in ventral grooming behaviour. Although such post-surgery changes in behaviour have been interpreted as indicative of analgesic bene®t (Liles e t a l. 1998 ) , the likelihood that some component of this change may have been due to non-speci®c effects of buprenorphine meant that it was im possible to determine the extent of analgesic effects due to treatm ent with buprenorphine. Grooming activity, and indeed many other acti vities (e.g. stretching, rearing) that had been considered potentially useful for assessing pain could not be used in this study (Roughan & Flecknell 2000 ) . In light of this, at the high dosage at which buprenorphine was adm inistered in the study by Gillingham e t a l. (2001 ) (0.5 mg=kg ¡1 every 6 h), major effects upon behaviour would be anticipated. In their study, it therefore also remains uncertain whether the effects observed in animals presumed to be experiencing pain were due to non-speci®c effects of buprenorphine upon behaviour, or to insuf®cient analgesia.
More recently, Roughan and Flecknell (2001 ) studied the post-operati ve behaviour of rats in even greater detail. T his work demonstrated that highly speci®c, previously unstudied components of behaviour may form the basis of a system for routine pain assessment and management in Wistar rat s subjected to laparot omy. T he behaviours identi®ed as useful indices of pain were twitching of the bac k and¯ank, a momentary loss of, or compromised balanc e (`fall'), à cat-like' arching of the bac k, and a squirming of the¯ank. In particular, twitching and back-arc hing occurred at measurable frequencies (200 =h and 20 =h, respectively) in rats given only saline prior to surgery, and were signi®cantly reduced following treatment with ketoprofen or carprofen (5 mg=kg 71 s.c.). As these drugs had negligible effects upon these, or indeed any of the other behaviours in control rats, twitching and bac k-arc hing were shown to be of considerable value in distinguishing between treatm ents following surgery, and hence, assessing analgesic ef®cacy. In additi on to the effects observed with carprofen and ketoprofen by a trained observer, preliminary data indicat e that the scoring system can be implemented by naõ Ève assessors. T he scoring system also appears to be effective in young rats of another strain (Fi sher344), and following a different surgical procedure (injection of tumour cells into the bladder wall) and with an alternative analgesic regimen (m eloxicam: another non-steroidal anti-in¯ammatory drug; NSAID), given orally or subcutaneously (Roughan & Flecknell, unpublished results) . Although non-speci®c effects on behaviour may still be a fact or, our most recent work using this speci®c behavioural scoring system has shown that buprenorphine (0.05 mg=kg ¡1 s.c.) causes a comparable reduction in the occurrence of the relevant behavioural indicators aft er this procedure (Roughan & Flecknell, unpublished results) .
When developing such pain assessment systems, in addit ion to controlling for non-speci®c drug effects, it is also im portant to identify any effects upon behaviour of the anaesthetics used (Liles & Flecknell 1992 ) and the type of pre-, intra-and post-operat ive care. T he potential for such in¯uences to disrupt behaviour has been demonstrated. A study by Tuli e t a l. (1994 ) showed a sig-ni®cant disruption of the behaviour of mice by merely moving animals to an adjacent room, while signi®cant behavioural effects resulting from similar movement of rats, and also commonly applied conditions during preparation for surgery (handling, anaesthesia and injections) have been documented (Roughan & Flecknell 2000 ) . In a recent attem pt to assess post-operative pain in mice, which recognized the potential for non-spe-ci®c effects of buprenorphine upon behaviour, a failure to control intra-operat ive body tem perature (which in some cases fell to below 25 C ) resulted in a masking of any analgesic effects (Hayes e t a l. 2000 ). T he results of these studies demonstrate a clear need for appropriate control groups in studies of the effects of surgery upon behaviour, which if not included, can make data regarding post-operati ve effects im possible to interpret reliably.
T he results of a number of clinical studies suggest that buprenorphine is an effective analgesic when it is given in circumstances of presumed severe post-operative pain (see Table 1 ). Pre-operatively administered morphine or buprenorphine have been shown to be effective in lowering subjective pain scores in dogs undergoing art hrotomy (Brodbelt e t a l. 1997) or in cats undergoing ovariohysterectomy (Slingsby & Waterman-Pearson 1998 , Stanway e t a l. 1996 , 2001 . However, it has been suggested, based largely on clinical im pression, that very substantial post-surgical pain is controlled more effectively by full mu agonists such as morphine rather than partial agonists such as buprenorphine or mixed agonist =antagon ist drugs such as butorphanol. T his may prove to be the case, although appropriately controlled clinical trials have yet to be conducted in animals. However, the analgesic ef®cacy of the different agents must be considered in conjunction with dat a concerning their duration of action. Although the duration of act ion of buprenorphine continues to be debated, it is clear that it has a longer period of ef®cacy than morphine, oxym orphone or pethidine. Introducing a regimen of repeated buprenorphine administration at intervals of 6±12 h may have practical implications, but repeated dosing of anim als with shorter acting opioids can cause even greater dif® culties. Staff considerations may limit the frequency of assessment or re-dosing, hence, a longer duration opioid such as buprenorphine may be the preferred treat ment even if it has a lesser maximal analgesic potency than a shorter acti ng drug such as morphine.
Other clinical issues
A side-effect of buprenorphine that has recently gained attenti on (Gades e t a l. 2001 ) is the ingestion of sawdust or wood-chip bedding known as pica behaviour (Clarke e t a l. 1997 , Bender 1998 . T his occurs when buprenorphine is administered within the clinically effective dose range of 0.03 mg= kg ¡1 (Bender 1998 ) to 0.3 mg=kg ¡1 (Clarke e t a l. 1997 ) and the gast ric obstruction can be suf®ciently serious to cause death (Jacobson 2000 ) . However, Jacobson found this could be eliminat ed by housing animals on grid oored cages for a short period following surgery, and, if this is not practical, by restricting access to bedding that is easily ingested. In these circumstances, rats receiving buprenorphine lost less weight following surgery than those receiving saline, and were therefore considered to be in less pain. Our own observations have also found this to be the case, as rat s housed on arti® cial bedding (`Dry-Bed', Drybed, Biggleswade, Bedfordshire, UK) rarely attem pt to ingest the mat erial following buprenorphine treat ment, show less post-operative weight loss and show improved food and water consumption compared with control (saline only) groups following surgery. Given the dramatic effects of pica behaviour, it seems that it is a relatively rare complicati on which is most apparent in anim als that are given unnecessarily high dosages of buprenorphine (0.3± 0.5 mg=kg ¡1 s.c.). If it does occur, then animals can either be housed on other material (e.g.`Dry-Bed') immediately post-operati vely (and this may be preferable for other reasons), or an alternative means of pain relief can be administered such as an NSAID (e.g. ketoprofen or carprofen). T he suggestion that the occurrence of the behaviour indicates distress, and that buprenorphine should not therefore be used in rodents (Clark e t a l. 1997) seems unsubstantiated. Pica behaviour could arise for many reasons, and may simply re¯ect the wide range of effects on behaviour that occur following adm inistration of opioids such as buprenorphine. Buprenorphine is normally administered by subcutaneous or intravenous dosing, although oral administration has been described (Pekow 1992 ). T his was recommended since it avoided the need to handle anim als following surgery. T he approach has been dem onstrat ed as successful in attenuating the reductions in food and water consumption and body weight that occur following laparotom y in rats (Liles e t a l. 1998, Flecknell e t a l. 1999 ). However, in a recent report by Mart in e t a l. (2001 ) rat s were given 0.5 mg=kg ¡1 buprenorphine in¯avoured gelat in (`buprenorphine jello') and this was shown to have no antinociceptive effect in a tai l-¯ick test. T he authors concluded that buprenorphine should be administered orally at 5 or 10 mg=kg ¡1 in order to sig-ni®cantly increase pain thresholds to the extent obtai ned with the currently recommended clinically effective dosage of 0.05 mg=kg ¡1 s.c. in rats. Most opioids, including buprenorphine, undergo signi®cant ®rst-pass extraction by the liver when administered by mouth. Brewster e t a l. (1981 ) demonstrated approxim at ely 10% plasma availabilit y of buprenorphine in rats following intraduodenal administration in comparison with intravenous dosing. T his equates approximately to the 10-fold difference between the subcutaneous and oral dosages that are most often cited (0.05 cf. 0.5 mg=kg ¡1 ). T his is supported by earlier analgesiometric data which reported an ED 50 in the rat tail pressure test of 0.016 mg=kg ¡1 i.p. and 0.35 mg=kg ¡1 per os (Cowan e t a l. 1977b), and also 0.005 mg=kg ¡1 buprenorphine given subcutaneously compared to 0.048 mg=kg ¡1 per os (Lewis & Cowan 1972 ) .
Similar results were also reported in the mouse-writhing test where an ED 50 of 0.03 mg=kg ¡1 (s.c.) compared with 0.19 mg=kg ¡1 per os (Lewis & Cowan 1972 ), and 0.02 mg=kg ¡1 (s.c.) and 0.4 mg=kg ¡1 per os was found by Matsuki e t a l. (1977 ) ( Table 2 ). T hus, it seemed an orally administered dosage of 0.5 mg=kg ¡1 should have availabilit y within a clinically effective range.
In contrast to the results of the analgesiometric study, controlled clinical trials (Lil es e t a l. 1998, Flecknell e t a l. 1999) indicat ed that even the 0.5 mg=kg ¡1 dosage is at the upper end of the scale of clinically effective oral dosages of buprenorphine. T he failure of Martin e t a l. (2001 ) to demonstrate a sig-ni®cant analgesic effect may have been due to a change in pH following mixing buprenorphine with jello. However, careful inspection of their methods suggests another explanation.
According to the product speci®cati on of the commercially avail able solution (`Buprenex', Reckitt and Coleman), buprenorphine should not be exposed to temperatures exceeding 40 C and decomposes at 60 C. Martin e t a l. (2001 ) stat e that they followed the original recipe of Pekow (1992) , however, in their study buprenorphine hydrochloride was added to gelatine solution at 55 C (and their injectable formulat ion was heated to an unspeci®ed temperature), while Pekow states that the gelat in solution should ®rst be allowed to cool to below 32 C before buprenorphine is added. Alternat ively, it may simply re¯ect differences in the strain of rat used, since other studies have clearly demonstrated the ef®cacy of orally administered buprenorphine (Tables 1 and 2) .
Clinical use of buprenorphine
We currently have relatively poor methods for assessing clinical pain in anim als, so recommendations for appropriate dose rates of a ny analgesics are dif® cult to make with con®dence. Given this note of caution, the large number of studies of the potency of buprenorphine in analgesiometric tests, coupled with data from a number of clinical trials, indicate that buprenorphine is valuable for controlling pain in a range of different species. We would not, however, advocate automatic selection of ®xed-dose or ®xed-drug regimens. Individual anim als and individual protocols should be exam ined critically, and a potentially suitable analgesic regimen form ulated. T his regimen should take into account issues such as use of preemptive analgesia, where adm inistration of analgesics before noxious stim ulation begins has the effect of preventing or minimizing the adverse effects upon the CNS that stimulation induces (Woolfe & Wall 1986 , Lascelles e t a l. 1995 . In the case of post-surgical pain relief, the analgesic protocol should be integrated into the anaesthetic protocol, since a further practical advantage of pre-emptive drug dosing can be a reduction in the dose of anaesthetic required, so reducing anaesthetic related side-effects. In circumstances where injectable agents such as ketam ine=medetomidine or pentobarbitone are used in rats, pre-anaesthetic administration of buprenorphine reduces the subsequent anaesthetic dosage by up to 20% (Roughan e t a l. 1999, Hedenqvist e t a l. 2000 ). It has also been reported that pre-anaesthetic administrat ion of 0.01, 0.03 or 0.1 mg=kg ¡1 buprenorphine results in a dose-dependent reduction of the MAC of iso¯urane in rats of, respectively, 15% , 30% or 50% (Criado e t a l.
2000; see also Flecknell & Waterman-Pearson 2000 ).
T here is, however, another important aspect to be considered before adopting an analgesic regimen involving partial agonists (such as buprenorphine) or mixed agonist=antagonists (such as butorphanol). If either drug has been administered, but has not fully controlled the animal's pain, it would be expected from the pharm acology of these agents that they may antagonize the effects of a subsequently administered pure mu agonist such as morphine. Although no controlled clinical trials have been undertaken, it appears that administration of morphine or oxymorphone in these circumstances does appear to produce an increased analgesic effect (Fl ecknell & Waterm an-Pearson 2000 ) .
If a pure mu agonist is used as the major component of an anaesthetic regimen e.g. when using a neuroleptanalgesic mixture such as fentanyl =¯uanisone or sufenta-nil=medetomidine, excellent intra-operative pain relief may be obtained. However, one disadvantage of use of such regimens is the possibility of anaesthetic complications due to respirat ory depression. Paradoxically, a further advan tage of use of mixed ago-nist=antagonists or partial agonists such as buprenorphine, is that they may be used to antagon ize the depressive effects of the pure mu agonist but maintain a good level of postoperative pain relief. T his technique, originally described as`anesthe Âsie=analge Âsique se Âquentielle' (De Castro & Viars 1968 ) has been demonstrated in both humans (Rifat 1972 , Robertson & Laing 1980 , Latasch e t a l. 1984 ) and anim als (Flecknell e t a l. 1989). Where other practical considerations limit the use of opioids, such as when contraindicated by a particular scienti®c programme, it might be appropriate to consider other agents such as NSAIDs that also have proven ef®cacy following procedures presumed to cause moderate to severe pain. An advantage of the use of these agents is that they appear to have fewer side-effects upon physiological status or behaviour; thus, assessment schemes may be developed without interference due to non-speci®c drug in¯uences. More detailed descriptions of the factors that require consideration prior to adopt ing a particular analgesic=anaesthetic regimen have been published (Fleck nell 1996 , Flecknell & Waterman-Pearson 2000 . Ultimat ely, the adequacy of the chosen analgesic regimen should then be evaluated using pain scoring techniques. At present, these are not well-developed, and further work is urgently needed.
Recommendations
We believe clear recommendations can be made regarding the use of buprenorphine for post-operative analgesia in anim als:
(1 ) Buprenorphine has proven safety and ef®cacy in large numbers of anim als, of a wide range of species. In a small number of animals it may produce undesirable side-effects such as pica or stereotypic behaviour. Pica may be avoided by use of alternat ive bedding material, otherwise, an alt ernat ive opioid analgesic or NSAIDs should be used.
(2 ) As with other opioids, the ef®cacy and duration of action will vary in different individuals and with different routes. T he most likely effective dosage will also depend on the severity of the procedure undertak en (clinically effective doses and administration routes for some common surgical procedures of varying severity are summarized in Table 1 ). Given that such variat ion will be clinically relevant makes it critically im portant that effective, well validated pain scoring systems are developed for post-surgical pain assessment. Once available, these assessment system s should be used to improve pain managem ent. (3 ) If analgesia is believed to be inadequate, then additional buprenorphine can be administered, since the`bell-shaped' dose response curve may have little clinical relevance (the dose at which analgesic effects might be reversed; >1 mg=kg ¡1 is outside the commonly recommended clinical range of 0.01±0.05 mg=kg ¡1 ). If buprenorphine does appear to be inadequate in controlling pain, perhaps due to à ceiling' effect or individual variation, other analgesics such as pure mu agonists, NSAIDs or local anaesthetics can be used.
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